# Regend Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/regend-therapeutics

- Industry: Biotechnology
- Headquarters: Suzhou, China
- Website: www.regend.cn
- Total disclosed funding: $52M
- Latest round: Series C (Feb 11, 2026)
- Investors on record: 14

## About

Established in 2015 and based in Suzhou, China, Suzhou Jimei Ruisheng Medical Technology Co., Ltd., trading as Regend Therapeutics, is a medical company that engages in the developing regenerative medicine products. In 2016, the company built GMP production bases in Shanghai and Suzhou. In 2017, the company established Zhejiang Jiangnan Stem Cell Research Institute. In 2018, the company established the subsidiary Jiangxi Xianhe Medical Technology Co., Ltd. In 2019, the company's bronchial basal lamina cells passed the inspection of the China Academy of Food and Drug Control. Prof. Wei Zuo, the founder, president and chief scientist of the company, worked in the laboratory of G Palade-M Farquhar, a Nobel Prize winner in physiology and medicine. In February 2026, Regend Therapeutics raised CNY 350 million in series C funding from Tibet Yuze Investment Management, Hefei High-tech Venture Capital, Hongtai Aplus, Hefei State-Owned Assets Holding, Fuho Capital, Tasly Capital Holdings Limited, China Universal Capital Investment Fund, and FIRHealth Capital.

The company's main products include Regend001, Regend007 and Regend005, etc. Regend001 is an autologous lung precursor cell suitable for the treatment of chronic obstructive pulmonary disease COPD, idiopathic pulmonary fibrosis IPF and interstitial lung disease. The company's research areas include adult stem cell isolation and expansion, stem cell therapy and renal regenerative medicine. The company’s revenue is generated by providing cell gene therapy products. The company will use the February 2026 funding to promote the clinical application of core products such as stem cells/progenitor cells.

## Funding rounds

- Series C, Feb 11, 2026, $50M — Fuho Capital, Hongtai Aplus, China Universal Capital Investment Fund, Hefei State-Owned Assets Holding, Hefei High-tech Venture Capital, Tasly Capital Holdings Limited, Tibet Yuze Investment Management, FIRHealth Capital
- Series B, Feb 10, 2025 — FIRHealth Capital
- Series B, Mar 3, 2022 — China Merchants Securities, Shenzhen Capital Real Estate Fund, Soochow Securities
- Series A, Dec 17, 2020 — InnoVision Capital
- Series A, Feb 1, 2017 — Guofu Jinyuan Capital
- Angel, Aug 6, 2015, $1.9M — JD Capital

## Investors

- JD Capital (https://capitalatlas.ai/funds/jd-capital) — Angel
- Guofu Jinyuan Capital (https://capitalatlas.ai/funds/guofu-jinyuan-capital) — Series A
- InnoVision Capital (https://capitalatlas.ai/funds/innovision-capital) — Series A
- China Merchants Securities — Series B
- Shenzhen Capital Real Estate Fund (https://capitalatlas.ai/funds/shenzhen-capital-real-estate-fund) — Series B
- Soochow Securities — Series B
- FIRHealth Capital (https://capitalatlas.ai/funds/firhealth-capital) — Series B, Series C
- Fuho Capital (https://capitalatlas.ai/funds/fuho-capital) — Series C
- Hongtai Aplus (https://capitalatlas.ai/funds/hongtai-aplus) — Series C
- China Universal Capital Investment Fund (https://capitalatlas.ai/funds/china-universal-capital-investment-fund) — Series C
- Hefei State-Owned Assets Holding (https://capitalatlas.ai/funds/hefei-state-owned-assets-holding) — Series C
- Hefei High-tech Venture Capital (https://capitalatlas.ai/funds/hefei-high-tech-venture-capital) — Series C
- Tasly Capital Holdings Limited (https://capitalatlas.ai/funds/tasly-capital-holdings-limited) — Series C
- Tibet Yuze Investment Management — Series C